Effects of concomitant combination of SGLT‐2 inhibitor and GLP‐1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series

Renal protection is likely to be a class effect of SGLT‐2 inhibitors and GLP‐1RA. When used simultaneously, there may be a synergistic effect. Both agents are also safe to use in high renal risk patients (eGFR between 21 and 30 mL/min/1.73m(2))

Detalles Bibliográficos
Autores principales: Kuhadiya, Nitesh D., Mahmood, Israa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077383/
https://www.ncbi.nlm.nih.gov/pubmed/33936685
http://dx.doi.org/10.1002/ccr3.4022
_version_ 1783684872932425728
author Kuhadiya, Nitesh D.
Mahmood, Israa
author_facet Kuhadiya, Nitesh D.
Mahmood, Israa
author_sort Kuhadiya, Nitesh D.
collection PubMed
description Renal protection is likely to be a class effect of SGLT‐2 inhibitors and GLP‐1RA. When used simultaneously, there may be a synergistic effect. Both agents are also safe to use in high renal risk patients (eGFR between 21 and 30 mL/min/1.73m(2))
format Online
Article
Text
id pubmed-8077383
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80773832021-04-29 Effects of concomitant combination of SGLT‐2 inhibitor and GLP‐1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series Kuhadiya, Nitesh D. Mahmood, Israa Clin Case Rep Case Reports Renal protection is likely to be a class effect of SGLT‐2 inhibitors and GLP‐1RA. When used simultaneously, there may be a synergistic effect. Both agents are also safe to use in high renal risk patients (eGFR between 21 and 30 mL/min/1.73m(2)) John Wiley and Sons Inc. 2021-03-09 /pmc/articles/PMC8077383/ /pubmed/33936685 http://dx.doi.org/10.1002/ccr3.4022 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Kuhadiya, Nitesh D.
Mahmood, Israa
Effects of concomitant combination of SGLT‐2 inhibitor and GLP‐1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series
title Effects of concomitant combination of SGLT‐2 inhibitor and GLP‐1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series
title_full Effects of concomitant combination of SGLT‐2 inhibitor and GLP‐1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series
title_fullStr Effects of concomitant combination of SGLT‐2 inhibitor and GLP‐1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series
title_full_unstemmed Effects of concomitant combination of SGLT‐2 inhibitor and GLP‐1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series
title_short Effects of concomitant combination of SGLT‐2 inhibitor and GLP‐1 receptor agonist on renal outcomes in T2D with eGFR below 30 and macroalbuminuria: A case series
title_sort effects of concomitant combination of sglt‐2 inhibitor and glp‐1 receptor agonist on renal outcomes in t2d with egfr below 30 and macroalbuminuria: a case series
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077383/
https://www.ncbi.nlm.nih.gov/pubmed/33936685
http://dx.doi.org/10.1002/ccr3.4022
work_keys_str_mv AT kuhadiyaniteshd effectsofconcomitantcombinationofsglt2inhibitorandglp1receptoragonistonrenaloutcomesint2dwithegfrbelow30andmacroalbuminuriaacaseseries
AT mahmoodisraa effectsofconcomitantcombinationofsglt2inhibitorandglp1receptoragonistonrenaloutcomesint2dwithegfrbelow30andmacroalbuminuriaacaseseries

Ejemplares similares